Page last updated: 2024-12-06

chrysomycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chrysomycin A is a polyketide-derived antibiotic produced by the bacterium Streptomyces griseus. It exhibits potent antibacterial activity against Gram-positive bacteria, including Staphylococcus aureus. Its unique structural features, including a 14-membered macrocycle with a conjugated polyene system, have attracted significant interest in the field of natural product chemistry. The biosynthetic pathway of chrysomycin A has been elucidated, revealing the involvement of a polyketide synthase (PKS) enzyme. Researchers are studying chrysomycin A for its potential as a new antibiotic drug candidate, particularly against multidrug-resistant bacterial strains. The compound's mechanism of action involves disrupting bacterial cell membrane integrity. However, its clinical application is limited due to its toxicity and instability. Ongoing research focuses on optimizing its pharmacological properties through chemical modifications to improve its therapeutic potential.'

chrysomycin A: Streptomyces arenae; differs only in sugar moiety from gilvocarcin V [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73468
CHEMBL ID4072918
CHEBI ID191084
MeSH IDM0107698

Synonyms (16)

Synonym
82196-88-1
chrysomycin a
chrysomycin a, >=98% (hplc), solid
CHEBI:191084
8-ethenyl-1-hydroxy-10,12-dimethoxy-4-[(2s,3s,4r,5s,6r)-3,4,5-trihydroxy-4,6-dimethyloxan-2-yl]naphtho[1,2-c]isochromen-6-one
6h-benzo(d)naphtho(1,2-b)pyran-6-one, 4-(6-deoxy-3-c-methyl-beta-gulopyranosyl)-8-ethenyl-1-hydroxy-10,12-dimethoxy-
chrysomycin v
nsc 613946
HB3835
chrysomycin a streptomyces sp
bdbm50235918
CHEMBL4072918 ,
HY-126771
CS-0107231
1-hydroxy-10,12-dimethoxy-4-((2s,3s,4r,5s,6r)-3,4,5-trihydroxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)-8-vinyl-6h-dibenzo[c,h]chromen-6-one
GLXC-26225

Research Excerpts

Effects

ExcerptReferenceRelevance
"Chrysomycin A (Chr-A) has been reported to inhibit the proliferation, migration and invasion of U251 and U87-MG cells through the Akt/GSK-3β signaling pathway, but the mechanism of Chr-A against glioblastoma in vivo and whether Chr-A modulates the apoptosis of neuroglioma cells is unclear."( Chrysomycin A Regulates Proliferation and Apoptosis of Neuroglioma Cells via the Akt/GSK-3β Signaling Pathway In Vivo and In Vitro.
Du, GH; Liu, DN; Liu, M; Shang, YF; Song, FH; Wang, YH; Zhang, HW; Zhang, SS; Zhang, WF, 2023
)
3.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)126.30000.05373.075710.0000AID1440267; AID1440271
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1440271Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) using L-Tryptophan as substrate after 25 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440268Inhibition of recombinant human IDO1 expressed in bacterial expression system at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440272Selectivity ratio of IC50 for recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) to IC50 for recombinant human IDO1 expressed in bacterial expression system2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440270Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440267Inhibition of recombinant human IDO1 expressed in bacterial expression system using L-Tryptophan as substrate after 25 mins in absence of GSH and presence of tween20 by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (22.22)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (22.22)24.3611
2020's10 (55.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.01 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]